Alector, Inc. filings document a Nasdaq-listed biotechnology issuer developing therapies for neurodegenerative diseases and reporting progress across the Alector Brain Carrier (ABC) platform. Its 8-K reports include operating and financial results, clinical and portfolio updates, material agreements, and officer appointments.
Regulatory documents also cover the company’s common stock, shelf registration statement and at-the-market equity sales agreement, along with governance matters in proxy materials such as board elections, executive compensation and shareholder voting items. Clinical disclosures address programs in Alzheimer’s disease, Parkinson’s disease, frontotemporal dementia and related neurological disorders, while event filings frame capital resources, platform development, trial outcomes and pipeline changes.
Alector, Inc. entered into an agreement granting Genentech exclusive worldwide rights to develop and commercialize its AL050 GCase program. Alector will receive a $100 million upfront payment and is eligible for up to $1.17 billion in development, regulatory and commercial milestone payments, plus tiered royalties on net sales.
Genentech will lead development, regulatory, manufacturing and commercialization. Alector retains its Alector Brain Carrier platform and rights to use it across its wholly owned pipeline outside GCase programs. After exercising its option and receiving the Genentech upfront payment, Alector will pay Spur Therapeutics $15 million, plus a percentage in the teens of certain sublicense income and additional royalties. Alector's preliminary, unaudited estimate of cash, cash equivalents and marketable securities was approximately $138.7 million as of September 30, 2026, and approximately $223.7 million on a pro forma basis after the agreements' initial payments. Alector said it believes this would fund operations into 2029.
Alector, Inc. (ALEC) is reported to have a significant shareholder group led by Biotechnology Value Fund entities and Mark N. Lampert, which together may be deemed to beneficially own 9,374,267 shares of Alector common stock as of September 18, 2026. This represents approximately 8.4% of the 111,656,919 shares outstanding as of July 31, 2026. The stake is held across several affiliated funds, including Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., and Biotechnology Value Trading Fund OS LP, with investment and voting authority allocated among related general partners and management entities. The reporting persons include various Delaware and Cayman Islands entities and Mark N. Lampert, who signs as authorized signatory for the group and disclaims beneficial ownership beyond the interests attributed through these entities.
Alector, Inc. (ALEC) reported that Principal Accounting Officer Grace Wong-Sarad sold a total of 9,446 shares of common stock in three open-market transactions on September 2–4, 2026. All reported sales were effected under a Rule 10b5-1 Trading Plan adopted on September 5, 2025, with one sale on September 3 disclosed as satisfying tax obligations related to vesting RSUs.
Alector, Inc. (ALEC) reported that its CFO & Chief Business Officer, Berkley Neil Lindsay, sold 29,251 shares of common stock on September 3, 2026 at a weighted average price of $2.6648 per share. The company reports the sale was made to satisfy the reporting person's tax obligations arising from the vesting of restricted stock units. Following this transaction, Lindsay directly holds 350,649 shares of Alector common stock. No Rule 10b5-1 trading plan is reported for this sale.
Alector, Inc. (ALEC) disclosed that Chief Executive Officer and director Arnon Rosenthal sold 72,606 shares of common stock on September 3, 2026 at a weighted average price of $2.6647 per share, with trades occurring between $2.49 and $2.75. The sale was made to satisfy the reporting person’s tax obligations related to vesting restricted stock units. After this transaction, he directly holds 2,294,600 shares of Alector common stock and also reports additional indirect holdings as trustee of several family trusts.
Alector, Inc. (ALEC) received a notice under Rule 144 that officer Grace Wong-Sarad plans to sell common stock through Morgan Stanley Smith Barney LLC. The planned sale covers 3,625 shares of restricted common stock, with an indicated aggregate market value of $9,094.40 as of the stated pricing date.
The notice also lists earlier sales of Alector common stock by the same person within the prior three months, which are relevant for Rule 144 volume calculations.
Alector, Inc. (ALEC) officer Grace Wong-Sarad has filed a notice under Rule 144 to sell 656 shares of common stock of Alector, Inc. through Morgan Stanley Smith Barney LLC, with a proposed sale date of September 2, 2026.
The filing also reports that Wong-Sarad sold 3,475 shares of common stock during the past three months for an aggregate amount of $6,542.73.
Alector, Inc. (ALEC) insider Grace Wong-Sarad filed a notice of proposed sale of company common stock under Rule 144. The shares relate to vested restricted stock units, with sales primarily intended to satisfy tax obligations arising from RSU vesting.
The planned sale involves common stock held at Morgan Stanley Smith Barney LLC Executive Financial Services and is to be executed on Nasdaq. The filing also lists prior Rule 144 sales of Alector common stock by the same person over the past three months.
Alector, Inc. (ALEC) is the issuer for a planned insider sale of common stock under Rule 144 by Arnon Rosenthal. The notice covers the proposed sale of 79,702 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $191,284.80, and an approximate sale date of September 2, 2026 on Nasdaq.
The securities relate to 156,646 shares received upon settlement of vested restricted stock units on September 1, 2026, with sales intended to satisfy tax obligations from this vesting. In the prior three months, Rosenthal sold 87,216 shares for proceeds of $172,188.09.
Alector, Inc. (symbol ALEC) received a notice under Rule 144 that Neil L. Berkley intends to sell shares of its common stock. The notice covers up to 63,095 shares, which were received upon vesting of restricted stock units on September 1, 2026, and are being sold to satisfy related tax obligations. Morgan Stanley Smith Barney LLC is listed as the broker. The filing also notes a prior sale of 19,360 shares of common stock during the past three months.